Shareholders’ meeting 2024
Results for ""
We found 472 results for your search.
Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 16, 2024
Availability of Transgene’s 2023 Universal Registration Document
URD 2023
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
TG4050 AACR 2024
Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al. AACR 2024 Abstract available on the AACR website – Download the poster Poster Presentation
Investor Access Event – April 5, 2024
2023 Fiscal Year Results
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
appointment Lucie Larguier et Christelle Schwoerer
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
2023 financial results and business update
Transgene Announces Upcoming Investor Meetings
upcoming investor meetings
